Human papilloma virus replication inhibitors
AssigneeIcosagen Cell Factory OÜ
InventorsMart USTAV, SR., Ene USTAV, Andres MÄNNIK, Mart TOOTS, Andres TOVER
Life of this patent
Estimating the term…
Abstract
Methods for treating high risk HPV infection by inhibiting one or more phases of HPV replication cycle with antiviral compounds are disclosed. Moreover, a mechanism for the inhibition is suggested and targets for further antiviral compounds are disclosed.
Claims12
A method to treat high risk HPV-infection, said method comprising administration of, or contacting infected cells with a compound capable of inhibiting one or more replication phases of Human Papilloma Virus, wherein the compound inhibits release of Topoisomerase I cleaving complex Top1cc from HPV DNA.
A method to inhibit one or more replication phases of high risk HPV in vitro or in vivo, said method comprising a step of contacting the infected cell with a compound inhibiting release of Topoisomerase I cleaving complex Top1cc from HPV DNA.
A method to treat high risk HPV infection, the method comprising a step of administration of, or contacting infected cells with any one of the compounds:
(canceled)
A method to identify potential antiviral compounds for inhibition of high risk HPV genome replication, said method comprising detection of compounds capable of inhibiting Tdp1 and PARP 1.
Dependencies are inferred from the claim text.